---
title: How I Treat on Infant Acute Lymphoblastic Leukemia
date: '2024-06-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38905593/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240622182853&v=2.18.0.post9+e462414
source: Blood
description: Infant acute lymphoblastic leukemia (ALL) is an aggressive malignancy
  that has historically been associated with a very poor prognosis. Despite large
  co-operative international trials and incremental increases in intensity of therapy,
  there has been no significant improvement in outcome over the last 3 decades. Using
  representative cases, we highlight the key differences between KMT2A-rearranged
  and KMT2A-germline infant ALL, and how advances in molecular diagnostics are unpicking
  ...
disable_comments: true
---
Infant acute lymphoblastic leukemia (ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Despite large co-operative international trials and incremental increases in intensity of therapy, there has been no significant improvement in outcome over the last 3 decades. Using representative cases, we highlight the key differences between KMT2A-rearranged and KMT2A-germline infant ALL, and how advances in molecular diagnostics are unpicking ...